Company intelligence / Profile preview

Afimmune

Dublin, Leinster, Irelandafimmune.com ↗
Ownership
Private
Employees
~10
Development stage
Other
01

Overview

Afimmune is a Dublin-based clinical-stage biotech focused on developing novel therapeutics—primarily small molecule bioactive lipids—for rare and inflammatory diseases. Its lead candidate, Epeleuton, targets sickle cell disease and has shown promising preclinical efficacy with ongoing Phase 2 trials in North America. The company has received orphan drug designation from the FDA for Epeleuton in SCD. Other pipeline assets are at earlier stages of development or have been discontinued for non-core indications such as diabetes mellitus type II.

Therapeutic areas
HematologyImmunologyEndocrinology
Modalities
small molecules (notably synthetic fatty acids such as Epeleuton)bioactive lipids
Industry
Biotech
02

Drug pipeline

3 assets

epeleuton

2

2 more assets in the full pipeline.

03

Partnerships

Pathway to Cures (venture philanthropy fund of the American National Bleeding Disorders Foundation)member of SCDAA’s SCD C.A.R.E.S. Consortium

Beyond the preview

Go deeper on Afimmune.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

  • Partners
  • Deal terms
  • Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

  • Funding rounds
  • Investors
  • Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

  • Peer companies
  • Targets
  • Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

  • Platforms
  • Patents
  • Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

  • Company news
  • Sources
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Afimmune.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call